![]() |
![]() |
![]() |
![]() |
150-P | COMPARATIVE ANALYSIS OF GENE REGULATORY NETWORKS IN LYMPHOID LEUKEMIAS USING THE INTERACTIVE HEMAP RESOURCE | Juha Mehtonen | ![]() |
![]() |
|||
152-P | HEDGEHOG PATHWAY ACTIVATION IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA PREDICTS RESPONSE TO SMO AND GLI1 INHIBITORS | Jolien De Bie | ![]() |
![]() |
|||
153-P | IDENTIFICATION OF CANDIDATE ONCOGENES AND CHROMOSOMAL BREAKPOINT SEQUENCING BY TARGETED LOCUS AMPLIFICATION IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | Eric Vroegindeweij | ![]() |
![]() |
|||
154-P | A PLATFORM FOR DETECTION OF FUSION GENES IN ALL FROM TARGET CAPTURE NEXT-GENERATION SEQUENCING OF DNA AND RNA. | Andrea Grioni | ![]() |
![]() |
|||
155-P | THE NUP214-ABL1 FUSION COOPERATES WITH TLX1 IN THE DEVELOPMENT OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | Marlies Vanden | ![]() |
![]() |
|||
157-P | CHARACTERIZATION OF AN EX VIVO T-CELL CULTURE MODEL FOR THE STUDY OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | Simon Bornschein Bempt | ![]() |
![]() |
|||
160-P | DEVELOPMENT OF A NOVEL FIRST-IN-CLASS ORAL INHIBITOR OF THE NOTCH PATHWAY. | Rajwinder Lehal Bempt | ![]() |
![]() |
|||
162-P | LOSS OF PIGH EXPRESSION FREQUENTLY RESULTS IN A GPI-NEGATIVE SUBCLONE LACKING CD52 MEMBRANE EXPRESSION, CONFERRING ALEMTUZUMAB RESISTANCE TO B CELL ACUTE LYMPHOBLASTIC LEUKEMIA | Inge JEDEMA | ![]() |
![]() |
|||
164-P | BABOON ENVELOPE PSEUDOTYPED LENTIVIRAL VECTORS: A HIGHLY EFFICIENT NEW TOOL TO GENETICALLY MANIPULATE T-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA INITIATING CELLS | Melania TESIO | ![]() |
![]() |
|||
165-P | HIGH INCIDENCE OF PHILADELPHIA CHROMOSOME-LIKE ACUTE LYMPHOBLASTIC LEUKEMIA (PH-LIKE ALL) IN OLDER ADULTS WITH B-ALL | Alexander Perl Bempt | ![]() |
![]() |
|||
168-P | THE COMBINATION OF BORTEZOMIB AND CHEMOTHERAPY IS AN EFFECTIVE TREATMENT TO RE-INDUCE REMISSION IN RELAPSED/REFRACTORY B-CELL PRECURSOR OR T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | Alice BERTAINA Bempt | ![]() |
![]() |
|||
169-P | EFFICACY OF FRONT-LINE TREATMENT COMBINATIONS WITH PONATINIB VERSUS 1ST- AND 2ND-GENERATION TYROSINE KINASE INHIBITORS FOR PH+ ACUTE LYMPHOBLASTIC LEUKEMIA: A META-ANALYSIS AND META-REGRESSION | Ariadne Souroutzidis Bempt | ![]() |
![]() |
|||
170-P | RISK OF CEREBRAL VEIN THROMBOSIS (CVT) IN ADULT ALL PATIENTS IN FINLAND 1999-2012: SUGGESTION FOR A LEUKEMIA-RELATED PREDICTIVE SCORING MODEL | Saara Roininen | ![]() |
![]() |
|||
171-P | INITIAL RESULTS FROM UKALL60+, A UK/HOVON COLLABORATIVE PHASE 2 STUDY IN ELDERLY PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKAEMIA. | Nick MORLEY Bempt | ![]() |
![]() |
|||
172-P | RELAPSE OF ACUTE LYMPHOBLASTIC LEUKAEMIA IN OLDER/ELDERLY PATIENTS - A SWEDISH POPULATION-BASED STUDY | Emma BERGFELT Bempt | ![]() |
![]() |
|||
173-LB | N. Toft | ![]() |
|
![]() |
|||
174-P | VENTX INDUCES EXPANSION OF PRIMITIVE ERYTHROID CELLS AND CONTRIBUTES TO THE DEVELOPMENT OF ACUTE MYELOID LEUKEMIA IN MICE | Eva Gentner Bempt | ![]() |
![]() |
|||
175-P | ABNORMAL INTRAGENIC TRANSCRIPTIONAL ACTIVATION IN MLL-AF9 AND KAT6A-CREBBP ACUTE MYELOID LEUKEMIA (AML) | Anna Marneth | ![]() |
![]() |
|||
176-P | HHEX TRANSFORMS PROMYELOCYTES AND COOPERATES WITH FACTOR INDEPENDENCE TO CAUSE PROMYELOCYTIC LEUKEMIA IN MICE | Jacob T Jackson | ![]() |
![]() |
|||
177-P | A SOMATIC MUTATION OF GFI1B IDENTIFIED IN LEUKEMIA ALTERS CELL FATE VIA A SPI1 (PU.1) CENTERED GENETIC REGULATORY NETWORK | Eduardo Anguita | ![]() |
![]() |
|||
181-P | TRIB2 TRANSFORMED GMP AS THE MYELOID LEUKEMIA INITIATING CELL | Krishna Yalla Jackson | ![]() |
![]() |
|||
182-P | TRIB2 REGULATES THE CELL CYCLE UNDER STRESS CONDITIONS IN A MURINE CELL MODEL OF LEUKEMIA. | Mara Salomè Bempt | ![]() |
![]() |
|||
183-P | CHROMOTHRIPSIS: A NEW MECHANISM OF CANCER INITIATION AND PROGRESSION IN ADULT ACUTE MYELOID LEUKEMIA | Giovanni Martinelli Bempt | ![]() |
![]() |
|||
184-P | AN EVALUATION OF THE TYROSINE KINASE INHIBITOR PACRITINIB IN PATIENTS WITH RELAPSED FLT3-MUTATED ACUTE MYELOID LEUKAEMIA (THE UK NCRI AML17 STUDY) | Steven Knapper Bempt | ![]() |
![]() |
|||
186-P | SAFETY STUDY OF CRENOLANIB, A TYPE I FLT3 INHIBITOR, WITH CYTARABINE/DAUNORUBICIN OR CYTARABINE/IDARUBICIN INDUCTION AND HIGH-DOSE CYTARABINE CONSOLIDATION IN NEWLY DIAGNOSED FLT3+ AML | Meghan Macaraeg Bempt | ![]() |
![]() |
|||
187-P | PHASE II STUDY OF CLADRIBINE AND LOW-DOSE ARAC ALTERNATING WITH DECITABINE IN OLDER PATIENTS WITH AML. | Tapan Kadia | ![]() |
![]() |
|||
188-P | DIFFERENTIATION RESPONSE TO GILTERITINIB (ASP2215) IN RELAPSED/REFRACTORY FLT3 MUTATED ACUTE MYELOID LEUKEMIA PATIENTS IS ASSOCIATED WITH CO-MUTATIONS IN NPM1 AND DNMT3A | Jonathan Canaani Bempt | ![]() |
![]() |
|||
190-P | CLINICAL RESPONSE IN RELAPSED/REFRACTORY AML PATIENTS CORRELATES WITH LEUKEMIC BLAST MOBILIZATION AND DIFFERENTIATION INDUCED BY BL-8040, A POTENT CXCR4 ANTAGONIST; RESULTS OF A PHASE IIA STUDY | Yaron Pereg | ![]() |
![]() |
|||
193-P | A PHASE I TRIAL OF A PHARMACODYNAMICALLY-CONCEIVED DECITABINE/THIOGUANINE COMBINATION IN PATIENTS WITH ADVANCED MYELOID MALIGNANCIES | Mark Frattini Bempt | ![]() |
![]() |
|||
194-P | GENOMIC CHARACTERIZATION OF HIGH-COUNT MBL INDIVIDUALS INDICATES THAT EARLY DETECTION OF DRIVER MUTATIONS AND SUBCLONAL EXPANSION ARE PREDICTORS OF ADVERSE CLINICAL OUTCOME | Santiago Barrio | ![]() |
![]() |
|||
195-P | IDENTIFICATION OF NOVEL B CELL RECEPTOR ANTIGENS IN CHRONIC LYMPHOCYTIC LEUKEMIA | Elisa ten | ![]() |
![]() |
|||
198-P | IN VIVO CHARACTERIZATION OF LYN KINASE IN THE PATHOGENESIS OF CHRONIC LYMPHOCYTIC LEUKEMIA | Phuong-Hien Nguyen Hacken | ![]() |
![]() |
|||
199-P | MICROENVIRONMENTAL STROMAL CELLS TRIGGER HYPOXIA SIGNALLING IN CLL CELLS – A MECHANISM THAT PROVIDES PROTECTION FROM APOPTOSIS AND CAN BE TARGETED THERAPEUTICALLY | Daniel Mertens | ![]() |
![]() |
|||
200-P | IBRUTINIB INHIBITS CD20 UP-REGULATION ON CLL B CELLS MEDIATED BY THE CXCR4/SDF-1 AXIS | Gabriela Pavlasova Hacken | ![]() |
![]() |
|||
201-P | FUNCTIONAL IMPACT OF BONE MARROW MESENCHYMAL STROMAL CELL-DERIVED EXTRACELLULAR VESICLES ON CHRONIC LYMPHOCYTIC LEUKEMIA B-CELLS: APOPTOSIS, MIGRATION, CHEMORESISTANCE AND GENE EXPRESSION MODIFICATION | Emerence Crompot | ![]() |
![]() |
|||
202-P | THE T-CELL/CLL/MACROPHAGE TRIAD SHAPES A SUPPORTIVE TUMOR MICROENVIRONMENT IN CLL | Martijn van Attekum | ![]() |
![]() |
|||
204-P | BLOCKING ENDOTHELIN-1 SIGNALING DISRUPTS LEUKEMIC CELL HOMING AND B-CELL RECEPTOR PATHWAY IN CHRONIC LYMPHOCYTIC LEUKEMIA | Rossana MAFFEI Attekum | ![]() |
![]() |
|||
205-P | GENE EXPRESSION PROFILES OF PERIPHERAL BLOOD T AND NK-CELLS REVEALED DIFFERENT PATTERNS OF IMMUNE DYSFUNCTION IN CLL-LIKE MBL AND EARLY STAGE CLL | Anna Puiggros | ![]() |
![]() |
|||
206-P | CD49D EXPRESSION IMPACTS ON THE IBRUTINIB-INDUCED LYMPHOCYTOSIS IN CHRONIC LYMPHOCYTIC LEUKEMIA: A ROLE OF BCR-MEDIATED INSIDE-OUT VLA-4 INTEGRIN ACTIVATION | Erika Tissino Attekum | ![]() |
![]() |
|||
210-P | PRELIMINARY RESULTS OF A PHASE II STUDY OF IBRUTINIB IN COMBINATION WITH FCR (IFCR) IN PREVIOUSLY UNTREATED, YOUNGER PATIENTS WITH CLL | Matthew Davids | ![]() |
![]() |
|||
211-P | PRESENCE OF MULTIPLE UNMUTATED IGHV REARRANGEMENTS IN CLL PATIENTS IS ASSOCIATED WITH A VERY SHORT TREATMENT–FREE SURVIVAL: RESULTS FROM 2 INDEPENDENT COHORTS | Basile Stamatopoulos | ![]() |
![]() |
|||
212-P | NON-CODING NOTCH1 MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKAEMIA; THEIR CLINICAL IMPACT IN THE CLL4 CLINICAL TRIAL | Marta Larrayoz Attekum | ![]() |
![]() |
|||
213-P | UPDATED RESULTS OF A PHASE 3 RANDOMIZED, CONTROLLED STUDY OF IDELALISIB IN COMBINATION WITH OFATUMUMAB FOR PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) | Timothy Dichiara Attekum | ![]() |
![]() |
|||
218-P | ULTRA DEEP TARGETED NEXT GENERATION SEQUENCING FOR THE DETECTION OF SUBCLONAL TP53 ABERRATIONS IN CLL | Christian Brieghel Attekum | ![]() |
![]() |
|||
219-P | COMPARABLE OUTCOMES IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH REDUCED DOSE IBRUTINIB: RESULTS FROM A MULTI-CENTER STUDY | Rahul Banerjee Attekum | ![]() |
![]() |
|||
221-P | PATIENTS WITH COMPLEX KARYOTYPE (CK) LACKING TP53 DELETIONS SHOW AN EQUIVALENT DISMAL CLINICAL OUTCOME AS THOSE WITH TP53 DELETIONS AND NON-CK IN CHRONIC LYMPHOCYTIC LEUKEMIA | Anna Puiggros Attekum | ![]() |
![]() |
|||
230-P | IMPACT OF SECOND DECLINE RATE OF BCR-ABL1 TRANSCRIPT BETWEEN M3 AND M6 ON CLINICAL OUTCOME FOR CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH IMATINIB: PRACTICAL ASPECT FOR THE TRUE LIFE | Stephanie DULUCQ Attekum | ![]() |
![]() |
|||
232-P | LATE RELAPSES, UP TO 45 MONTHS AFTER IMATINIB DISCONTINUATION: RESULTS FROM THE ISAV STUDY | Silvia Mori Attekum | ![]() |
![]() |
|||
233-P | ASSESSMENT OF THERAPY RESPONSE IN CHRONIC MYELOID LEUKEMIA VIA 1 MONTH BCR-ABL1 TRANSCRIPT DECLINE | Mohamed El Missiry | ![]() |
![]() |
|||
234-P | DEVELOPMENT AND EVALUATION OF A MR1 – MR4.5 SECONDARY LYOPHILIZED CELL REFERENCE PANEL FOR BCR-ABL1 QUANTIFICATION ON THE INTERNATIONAL SCALE | Connie Wong Missiry | ![]() |
![]() |
|||
235-P | TYROSINE KINASE INHIBITORS DISCONTINUATION IN CHRONIC MYELOID LEUKEMIA: A RETROSPECTIVE ANALYSIS OF 208 ITALIAN PATIENTS | Carmen FAVA | ![]() |
![]() |
|||
236-P | MANAGING CHILDREN AND ADOLESCENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH HIGH-DOSE IMATINIB. THE ITALIAN EXPERIENCE. | Fiorina Giona Attekum | ![]() |
![]() |
|||
238-P | VITAMIN C INCREASES VIRAL MIMICRY INDUCED BY 5-AZA-2-DEOXYCYTIDINE | Andreas Due Ørskov | ![]() |
![]() |
|||
239-P | GENETIC PREDISPOSITIONS TO SPORADIC MYELOID NEOPLASMS CAUSED BY GERMLINE DDX41 MUTATIONS IN ASIAN AND CAUCASIAN POPULATIONS. | June Takeda Ørskov | ![]() |
![]() |
|||
240-P | IDENTIFICATION OF ALTERED AND CRYPTIC-SPLICING IN SF3B1 MUTANT MYELODYSPLASTIC SYNDROMES AND ISOGENIC MODELS OF SF3B1-K700E MUTATION | Fabio Liberante | ![]() |
![]() |
|||
241-P | IMPACT OF SOMATIC MUTATIONS ON OUTCOME IN PATIENTS WITH MDS AFTER STEM-CELL TRANSPLANTATION | Tetsuichi Yoshizato | ![]() |
![]() |
|||
242-P | 17P DELETIONS AND TP53 MUTATIONS IN PATIENTS WITH MDS/AML AND COMPLEX ABERRANT KARYOTYPE | Roxana Schaab Ørskov | ![]() |
![]() |
|||
243-P | TP53 AND EZH2 MUTATIONS PREDICT POOR SURVIVAL IN PATIENTS TREATED WITH HYPOMETHYLATING AGENTS IN MDS | M Teresa Cedena | ![]() |
![]() |
|||
244-P | AZACYTIDINE RESTORES THE ABNORMAL STAT SIGNALING BIOSIGNATURE OF FOXP3+ T REGULATORY CELLS (TREGS) IN RESPONDING MDS PATIENTS. | Ioannis KOTSIANIDIS | ![]() |
![]() |
|||
245-P | A CULTURE MODEL MIMICKING THE BM-NICHE ALLOWS FOR STUDYING THE DYSREGULATED ERYTHROPOIESIS OF SF3B1 MUTATED MYELODYSPLASTIC SYNDROME WITH RINGED SIDEROBLASTS | Edda María Elvarsdóttir | ![]() |
![]() |
|||
246-P | THE INCIDENCE AND CLINICAL IMPLICATIONS OF CHROMOTHRIPSIS IN BONE MARROW CELLS OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) | Zuzana Zemanova | ![]() |
![]() |
|||
247-P | MODEST EPIGENETIC EFFECT OF AZACITIDINE IN GENOME-WIDE MAPPING OF DNA METHYLATION, H3K9ME3, H3K18AC AND GENE EXPRESSION IN MDS PROGENITORS. | Magnus Tobiasson Elvarsdóttir | ![]() |
![]() |
|||
248-P | RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY EVALUATING EPOETIN ALFA VERSUS PLACEBO IN ANEMIC PATIENTS WITH IPSS LOW- INT1 RISK MDS | Wayne Elwood | ![]() |
![]() |
|||
250-P | MUTATIONS OF COHESIN COMPLEX GENES IN MYELODYSPLASTIC SYNDROME: DISTINCT CLINIC-BIOLOGICAL FEATURES AND PROGNOSTIC RELEVANCE | Lo-Ho Chen Elvarsdóttir | ![]() |
![]() |
|||
252-P | CLINICAL BENEFIT AMONG LENALIDOMIDE (LEN)-TREATED PATIENTS (PTS) WITH RBC TRANSFUSION-DEPENDENT (RBC-TD) LOW-/INT-1-RISK MYELODYSPLASTIC SYNDROMES (MDS) WITHOUT DEL(5Q) | Guillermo Garcia-Manero Elvarsdóttir | ![]() |
![]() |
|||
254-P | THE USE OF A HIGH DENSITY, 2.6 MILLION MARKER, SNP ARRAY AS THE PRIMARY GENETIC TEST FOR MYELODYSPLASTIC SYNDROME AT DIAGNOSIS: INTERIM FINDINGS OF THE WEST MIDLANDS, UK STUDY | Nicola Trim Elvarsdóttir | ![]() |
![]() |
|||
257-P | FREQUENT MUTATIONS IN EPIGENETIC REGULATORS IN CYTOPENIA OF UNDETERMINED SIGNIFICANCE: ASSOCIATION WITH RISK OF PROGRESSION TO MYELODYSPLASTIC SYNDROME | Jakob Werner Hansen | ![]() |
![]() |
|||
258-P | MOLECULAR AND CLINICAL TYPES OF PLASMA CELL DYSCRASIAS ARE ASSOCIATED WITH DISTINCT EXPRESSION PATTERNS OF LONG NONCODING RNAS | Martina Manzoni Hansen | ![]() |
![]() |
|||
259-P | RPL5 ON 1P22 IS RECURRENTLY DELETED IN MULTIPLE MYELOMA AND ITS EXPRESSION IS LINKED TO BORTEZOMIB RESPONSE | Isabel Hofman Hansen | ![]() |
![]() |
|||
260-P | COMPREHENSIVE CHARACTERIZATION OF THE GENOMIC LANDSCAPE OF MULTIPLE MYELOMA WITH A DELETION OF CHROMOSOME 17P REVEALS A HIGH PREVALENCE OF SOMATIC TP53 MUTATIONS, WHICH CORRELATE WITH A POOR PROGNOSIS | Davine Hofste op | ![]() |
![]() |
|||
261-P | DEPENDENCE ON GLUTAMINE UPTAKE OF MYELOMA CELLS DELINEATES A NEW ATTRACTIVE THERAPEUTIC STRATEGY | Nicola GIULIANI | ![]() |
![]() |
|||
262-P | LOSS OF PRIMING OR MCL-1 DEPENDENCY CONFERRED ACQUIRED RESISTANCE TO VENETOCLAX IN MULTIPLE MYELOMA | Martine Amiot op | ![]() |
![]() |
|||
263-P | LOSS OF THE INHIBITORY RECEPTOR CD85J/LILRB1 ON MALIGNANT PLASMA CELLS: FROM MGUS TO SYMPTOMATIC MULTIPLE MYELOMA | Ester Lozano op | ![]() |
![]() |
|||
264-P | PROTEIN KINASE CK1A INACTIVATION IN MULTIPLE MYELOMA EMPOWERS LENALIDOMIDE INDUCED CYTOTOXICITY AND CELL CYCLE ARREST | Sabrina Manni | ![]() |
![]() |
|||
265-P | QUANTIFICATION OF CYCLIN D1, CYCLIN D2, IKAROS, AIOLOS AND CEREBLON PROTEINS BY CAPILARY IMMUNOASSAY IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AND ANALYSIS OF THEIR IMPACT ON PATIENT SURVIVAL | Irena Misiewicz-Krzeminska op | ![]() |
![]() |
|||
266-P | DEFERASIROX INDUCES APOPTOSIS THROUGH INHIBITION OF ONCOGENIC PYK2/BETA-CATENIN SIGNALING IN MULTIPLE MYELOMA CELLS | Kohichi Takada op | ![]() |
![]() |
|||
267-P | DEVELOPMENT AND IMPLEMENTATION OF A HIGH-THROUGHPUT SEQUENCING BASED, CLINICALLY-FOCUSED, COMPREHENSIVE GENOMIC CHARACTERISATION OF MYELOMA WITHIN A MOLECULAR DIAGNOSTIC SERVICE | Piers Blombery | ![]() |
![]() |
|||
276-P | THE SKY92 PROGNOSTIC MARKER IS VALIDATED IN EIGHT MULTIPLE MYELOMA CLINICAL DATASETS | Martin Van Vliet | ![]() |
![]() |
|||
279-P | MOR202 ALONE AND IN COMBINATION WITH POMALIDOMIDE OR LENALIDOMIDE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: DATA FROM CLINICALLY RELEVANT COHORTS FROM A PHASE I/IIA STUDY | Marc Raab Vliet | ![]() |
![]() |
|||
281-P | FINAL PHASE 2 STUDY DATA OF MELFLUFEN AND DEXAMETHASONE FOR PATIENTS WITH RELAPSED-REFRACTORY MULTIPLE MYELOMA (RRMM) | Eva Nordström | ![]() |
![]() |
|||
282-P | PRECISION AS PART OF THE ANALYTICAL VALIDATION OF THE SKY92 HIGH RISK SIGNATURE AND THE MMPROFILER ASSAY | Martin Van Vliet | ![]() |
![]() |
|||
283-P | RISK STRATIFICATION BY SKY92+ISS OUTPERFORMS IFISH MARKERS T(4;14) AND DEL(17P) IN MULTIPLE MYELOMA | Martin Van Vliet | ![]() |
![]() |
|||
284-P | CONSOLIDATION WITH BORTEZOMIB AND LENALIDOMIDE POST-ASCT WITHOUT DEXAMETHASONE AND BISPHOSPHONATES: FINAL ANALYSIS OF A PROSPECTIVE STUDY IN NEWLY DIAGNOSED MYELOMA PATIENTS | Dimitrios Christoulas Vliet | ![]() |
![]() |
|||
285-P | LOW INCIDENCE OF SKELETAL-RELATED EVENTS AT THE TIME OF FIRST RELAPSE IN PATIENTS WITH MULTIPLE MYELOMA WHO RECEIVED BORTEZOMIB-BASED REGIMENS AS FIRST LINE TREATMENT | Dimitrios Christoulas Vliet | ![]() |
![]() |
|||
287-P | CONCURRENT INHIBITION OF PI3K/MTOR AND JAK1/JAK2 PATHWAYS PROMPTS COMPLETE DEPHOSPHORYLATION OF STAT5 PROVIDING SYNERGISTIC ACTIVITY IN MPN MODELS | Manjola Balliu Vliet | ![]() |
![]() |
|||
290-P | LNK MUTATIONS IN FAMILIAL MYELOPROLIFERATIVE NEOPLASMS | Elisa Rumi | ![]() |
![]() |
|||
291-P | HOMOZYGOUS CALRETICULIN MUTATIONS IN PATIENTS WITH MYELOFIBROSIS LEAD TO ACQUIRED MYELOPEROXIDASE DEFICIENCY | Alexandre THEOCHARIDES Vliet | ![]() |
![]() |
|||
293-P | MESENCHYMAL STROMAL CELLS (MSC) FROM HIGH-GRADE BONE MARROW FIBROSIS PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS (PH-NEG MPN) DISPLAY REDUCED CLONOGENICITY AND PROLIFERATION CAPACITY. | Benedetta RAMBALDI Vliet | ![]() |
![]() |
|||
294-P | NEXT-GENERATION SEQUENCING IDENTIFIES MPL-TET2 MUTATED CLONES IN A SUBSET OF PATIENTS WITH JAK2V617F-POSITIVE MYELOFIBROSIS | Haifa Kathrin AL-ALI | ![]() |
![]() |
|||
297-LB | Christian Pecquet | ![]() |
|
![]() |
|||
298-P | CLINICAL IMPACT OF ONCOGENETIC PROFILES IN SYSTEMIC MASTOCYTOSIS WITH AN ASSOCIATED HEMATOLOGICAL NON-MAST CELL DISEASE. | Carlos Fernandez | ![]() |
![]() |
|||
299-P | MUTATIONAL STUDY OF GENES INVOLVED IN MYELOFIBROSIS BY MASSIVE SEQUENCING | Ana Africa Martin | ![]() |
![]() |
|||
301-P | PREVENTION OF THROMBOSIS IN PATIENTS WITH POLYCYTHEMIA VERA TREATED WITH HYDROXUYUREA PLUS PHLEBOTOMIES OR HYDROXYUREA ALONE | Alberto Alvarez-Larrán | ![]() |
![]() |
|||
302-P | RATE OF MALIGNANT TRANSFORMATION IN HIGH RISK ET DURING 5 YEARS OF FOLLOW-UP OF CYTOREDUCTIVE THERAPY | Gunnar BIRGEGÅRD Martin | ![]() |
![]() |
|||
304-LB | C. Harrison | ![]() |
|
![]() |
|||
309-P | THE LYMPHOMA ASSOCIATED MACROPHAGES-HODGKIN/REED-STERNBERG CELLS RATIO IS A POOR PROGNOSTIC FACTOR IN CLASSIC HODGKIN LYMPHOMA PATIENTS | Vit Prochazka | ![]() |
![]() |
|||
310-P | THE PROGNOSTIC ROLE OF BCL-2 EXPRESSION IN PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA ASSESSED FOR CD68+ CELL COUNT. | Annarosa cuccaro Martin | ![]() |
![]() |
|||
312-P | BIOLOGICALLY MEANINGFUL CHANGES IN CYTOKINE AND CHEMOKINE PRODUCTION FOLLOWING IBRUTINIB THERAPY IN WALDENSTROM´S MACROGLOBULINEMIA. | Josephine VOS Martin | ![]() |
![]() |
|||
316-P | THE COMBINATION OF IBRUTINIB AND VENETOCLAX (ABT-199) RAPIDLY ACHIEVES COMPLETE REMISSIONS IN PATIENTS WITH RELAPSED / REFRACTORY MANTLE CELL LYMPHOMA: PRELIMINARY RESULTS OF THE PHASE II AIM STUDY | Constantine Tam Martin | ![]() |
![]() |
|||
318-P | PHASE 2A STUDY OF THE PHOSPHATIDYLINOSITOL-3-KINASE (PI3K) INHIBITOR COPANLISIB IN PATIENTS WITH RELAPSED/REFRACTORY, INDOLENT OR AGGRESSIVE LYMPHOMA | Dennis Healy Martin | ![]() |
![]() |
|||
320-P | SAFETY AND EFFICACY PROFILES OF CLARITHROMYCIN MONOTHERAPY IN 55 PATIENTS WITH EXTRANODAL MARGINAL ZONE LYMPHOMA (EMZL) | Caterina Cecchetti Martin | ![]() |
![]() |
|||
322-P | TO SCREEN BIOLOGICAL MARKER GENE ASSOCIATED WITH B CELL IN CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) PATIENTS | Depei Wu Martin | ![]() |
![]() |
|||
324-P | MESENCHYMAL STROMAL CELLS STIMULATE THE PROLIFERATION AND IL-22 PRODUCTION BY TYPE 3 INNATE LYMPHOID CELLS | Mette Hazenberg Martin | ![]() |
![]() |
|||
325-P | GRANULOCYTE COLONY-STIMULATING FACTOR MOBILIZATION INCREASES THE PROPORTION OF REGULATORY GAMMA DELT T CELLS | Qifa Liu | ![]() |
![]() |
|||
326-P | PREACTIVATED MESENCHYMAL STROMAL CELLS IMPROVE T-CELL REGENERATION AFTER THEIR COTRANSPLANTATION WITH HEMATOPOIETIC STEM CELLS | Selim Kuci | ![]() |
![]() |
|||
327-P | EVIDENCE OF COMPLEMENT DYSREGULATION IN TRANSPLANT – ASSOCIATED THROMBOTIC MICROANGIOPATHY | Eleni Gavriilaki | ![]() |
![]() |
|||
328-P | FAMILY-DIRECTED CORD BLOOD BANKING FOR SICKLE CELL DISEASE: A 20-YEAR EXPERIENCE, ON BEHALF OF EUROCORD-MONACORD AND THE INTERNATIONAL SICKLE CELL DISEASE OBSERVATORY. | Hanadi Rafii Martin | ![]() |
![]() |
|||
329-P | CONSOLIDATION BY ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN CR1 AGED 40-69 YEARS: A COMPARISON OF MYELOABLATIVE AND REDUCED INTENSITY CONDITIONING | Aniko Szabo Martin | ![]() |
![]() |
|||
330-P | RELAPSED/REFRACTORY HIGH GRADE B CELL NON-HODGKIN LYMPHOMA: SHOULD ONGOING PET POSITIVITY PRECLUDE AUTOLOGOUS TRANSPLANTATION IN PATIENTS ATTAINING A CT RESPONSE TO SALVAGE CHEMOTHERAPY? | Nagah Elmusharaf Martin | ![]() |
![]() |
|||
331-P | MARAVIROC CONCENTRATIONS ARE HIGHLY PREDICTIVE OF ACUTE GRAFT-VERSUS-HOST DISEASE IN REDUCED-INTENSITY ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION | Alex Ganetsky Martin | ![]() |
![]() |
|||
332-P | HYPERACUTE GRAFT VERSUS HOST DISEASE: RISK FACTORS, OUTCOMES AND IMPACT OF TACROLIMUS/SIROLIMUS PROPHYLAXIS. | Oriana Lopez | ![]() |
![]() |
|||
333-P | REDUCED INTENSITY CONDITIONING TRANSPLANTATION (RIC) AS PART OF FIRST LINE THERAPY FOR MANTLE CELL LYMPHOMA: RESULTS FROM THE PHASE II MINI ALLO TRIAL (CRUK: C7627/A9080) | Simon Rule | ![]() |
![]() |
|||
334-P | THE ROLL OF HYPOMETHYLATING AGENTS IN MYELOID RELAPSES AFTER ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANT. | Félix López Cadenas | ![]() |
![]() |
|||
335-P | IMPROVED CLINICAL OUTCOMES OF GBM/GPB MIXTURE HAPLOIDENTICAL TRANSPLANTATION WHEN COMPARED TO A PROPENSITY SCORE-MATCHED GPB HAPLOIDENTICAL TRANSPLANTATION: A MULTICENTER STUDY | Xiangyu zhao | ![]() |
![]() |
|||
336-P | TREATMENT OF CHRONIC GRAFT VERSUS HOST DISEASE WITH A COMBINATION OF B-CELL DEPLETION AND TYROSINE KINASE INHIBITION | Lotte VAN | ![]() |
![]() |
|||
337-P | FIRST-LINE EXTRACORPOREAL PHOTOCHEMOTHERAPY (ECP) FOR ACUTE GVHD AFTER ALLOGENEIC STEM CELL TRANSPLANTATION | Andrea RIMONDO Godino | ![]() |
![]() |
|||
338-P | EFFICACY OF HOST-DENDRITIC CELL VACCINATIONS WITH AND WITHOUT MINOR HISTOCOMPATIBILITY ANTIGEN LOADING, COMBINED WITH DONOR LYMPHOCYTE INFUSION IN MULTIPLE MYELOMA PATIENTS | Rimke Oostvogels DER | ![]() |
![]() |
|||
339-P | TRACING OF URINARY EXCRETION OF BKV AND JCV BY QUANTITATIVE PCR IN RECIPIENTS OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTS (ALLO-HSCT) TO ANTICIPATE THE DEVELOPMENT OF HEMORRHAGIC CYSTITIS (HC). | Joud Zanabili Al-Sibai | ![]() |
![]() |
|||
340-P | OUTCOMES AFTER AUTOLOGOUS AND ALLOGENEIC STEM CELL TRANSPLANTATION (SCT) IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) PATIENTS WITH MYC/BCL2 CO-EXPRESSION, DOUBLE-HIT LYMPHOMA, OR MYC COPY GAIN | Alex Herrera Al-Sibai | ![]() |
![]() |
|||
341-P | BTLA GENOTYPE AND CLINICAL OUTCOME AFTER HLA-IDENTICAL SIBLING STEM CELL TRANSPLANTATION | Nazly Santos Al-Sibai | ![]() |
![]() |
|||
342-P | HIGH-DOSE VERSUS STANDARD-DOSE RITUXIMAB WITH BEAM IN AUTOLOGOUS STEM CELL TRANSPLANTATION (SCT) FOR RELAPSED AGGRESSIVE B-CELL NON-HODGKIN´S LYMPHOMAS (NHL) | Samer Srour Al-Sibai | ![]() |
![]() |
|||
345-P | HIGH DOSE CHEMOTHERAPY WITH AUTOGRAFT MAY IMPROVE THE POOR PROGNOSIS OF NAIVE DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS WITH MYC/BCL2 CO-EXPRESSION | Francesco Maura Al-Sibai | ![]() |
![]() |
|||
346-P | BIOMARKERS PREDICTING ACUTE GRAFT-VERSUS-HOST DISEASE IN ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS: A PROSPECTIVE STUDY IN 120 PATIENTS | Linda Cheyenne | ![]() |
![]() |
|||
348-P | TRANSPLANTATION FROM MATCHED UNRELATED AND HAPLOIDENTICAL DONOR IN PEDIATRIC SEVERE APLASTIC ANEMIA: EXPERIENCE WITH TCR ALPHA/BETA AND CD19 DEPLETION AS GRAFT PROCESSING METHOD. | Daria SHASHELEVA Vaccari | ![]() |
![]() |
|||
350-P | HHEX PROMOTES HSC SELF-RENEWAL AND STRESS HEMATOPOIESIS VIA REPRESSION OF CDKN2A | Jacob T Jackson | ![]() |
![]() |
|||
352-P | NPM1 IS REQUIRED FOR NORMAL HEMATOPOIESIS | Chow Hiang Ang | ![]() |
![]() |
|||
353-P | PLZF MUTATION ALTERS MOUSE HEMATOPOIETIC STEM CELL FUNCTION AND CELL CYCLE PROGRESSION | Christelle VINCENT-FABERT Ang | ![]() |
![]() |
|||
354-P | IL-1 INDUCED ACTIVATION OF QUIESCENT HEMATOPOIETIC STEM CELLS IN VIVO | Uta Demel Vaccari | ![]() |
![]() |
|||
356-P | CLEC-2 EXPRESSION IS A NEW MARKER FOR A SUBSET OF HEMATOPOIETIC STEM/PROGENITOR CELLS THAT CONTRIBUTES TO INFLAMMATION-INDUCED EMERGENT MEGAKARYOPOIESIS | Takahiro Kumode Vaccari | ![]() |
![]() |
|||
357-P | IN VITRO AND IN VIVO STEM CELL PROPERTIES OF HIGHLY ENRICHED HUMAN BONE MARROW MESENCHYMAL STROMAL CELLS | Roshanak Ghazanfari | ![]() |
![]() |
|||
358-P | GENOME WIDE DYSREGULATION OF GENE EXPRESSION BY TRISOMY 21 IN FETAL LIVER HAEMATOPOIETIC STEM AND PROGENITOR CELLS | Anindita Roy Vaccari | ![]() |
![]() |
|||
359-P | GPR56: A NOVEL MOLECULE INVOLVED IN HEMATOPOIETIC STEM CELL GENERATION | Emma DE PATER | ![]() |
![]() |
|||
364-P | CORD BLOOD DERIVED NK CELLS TRANSFER HISTONE H2AZ TO MULTIPLE MYELOMA CELLS CAUSING DIRECT AND INDIRECT CYTOTOXICITY | Beatriz Martín-Antonio PATER | ![]() |
![]() |
|||
365-P | ALLOGENEIC TCRA/CD38 DOUBLE KNOCKOUT T-CELLS BEARING AN ANTI-CD38 CHIMERIC ANTIGEN RECEPTOR: AN IMPROVED IMMUNOTHERAPY FOR THE TREATMENT OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AND MULTIPLE MYELOMA. | Mathilde Dusseaux PATER | ![]() |
![]() |
|||
366-P | OPTIMIZED AAV-MEDIATED HUMAN FACTOR VIII GENE THERAPY IN HEMOPHILIA A MICE AND CYNOMOLGUS MACAQUES | James Wilson PATER | ![]() |
![]() |
|||
367-P | A DOSE-ESCALATING PRECLINICAL STUDY TO DETERMINE THE SAFETY, EFFICACY, AND MINIMUM EFFECTIVE DOSE OF A CLINICAL CANDIDATE VECTOR IN A MOUSE MODEL OF HEMOPHILIA B | James Wilson PATER | ![]() |
![]() |
|||
368-P | THE LCR-FREE GAMMA-GLOBIN LENTIVIRAL VECTOR COMBINING TWO HPFH ACTIVATING ELEMENTS CORRECTS MURINE THALASSEMIC PHENOTYPE IN VIVO | Nicholas Anagnou | ![]() |
![]() |
|||
369-P | BALANCE OF ANTI-CD123 CHIMERIC ANTIGEN RECEPTOR (CAR) BINDING AFFINITY AND DENSITY IN AN IN VITRO MODEL OF ACUTE MYELOID LEUKEMIA | Silvia Arcangeli | ![]() |
![]() |
|||
370-P | PHARMACOKINETICS (PK) AND PHARMACODYNAMICS (PD) OF GBT440, A NOVEL HEMOGLOBIN S (HBS) POLYMERIZATION INHIBITOR FOR THE TREATMENT OF SICKLE CELL DISEASE (SCD), IN HEALTHY VOLUNTEERS AND SCD PATIENTS | Mira Patel PATER | ![]() |
![]() |
|||
372-P | CEREBROVASCULAR RESERVE IN SICKLE CELL DISEASE ASSESSED WITH PERFUSION MAGNETIC RESONANCE IMAGING | Lena Vaclavu | ![]() |
![]() |
|||
373-P | RESTING STATE FUNCTIONAL MRI SHOWS HOW COGNITIVE PERFORMANCES COULD BE PRESERVED IN CHILDREN WITH SICKLE CELL DISEASE | Raffaella Colombatti PATER | ![]() |
![]() |
|||
377-P | ASSOCIATION BETWEEN ENVIRONMENTAL FACTORS AND HOSPITAL ADMISSIONS FOR SICKLE CELL DISEASE: A RETROSPECTIVE TIME SERIES ANALYSIS | Sanjay Tewari PATER | ![]() |
![]() |
|||
378-P | MULTICENTER, PROSPECTIVE, RANDOMIZED TRIAL OF INTRAVENOUS ITRACONAZOLE VS. LIPOSOMAL AMPHOTERICIN B AS EMPIRICAL ANTIFUNGAL THERAPY FOR HEMATOLOGICAL MALIGNANCY WITH PERSISTENT FEVER AND NEUTROPENIA | Isao Yoshida PATER | ![]() |
![]() |
|||
379-P | PREVALENCE, STRUCTURE, AND PUTATIVE MECHANISM FOR TEMPLATED INSERTIONS IN VDJ RECOMBINATION | Marvyn Koning PATER | ![]() |
![]() |
|||
380-P | FLUOROQUINOLONE PROPHYLAXIS SIGNIFICANTLY AFFECTS BACTERIAL EPIDEMIOLOLOGY AND ANTIBIOTIC RESISTANCE BUT DOES NOT IMPACT ON INCIDENCE AND MORTALITY OF BLOODSTREAM INFECTIONS IN ACUTE LEUKAEMIA | Chiara CATTANEO PATER | ![]() |
![]() |
|||
383-P | INVASIVE FUNGAL INFECTIONS IN LYMPHOPROLIFERATIVE DISORDERS: REVISION OF INCIDENCE IN THE "MODERN TREATMENT" ERA | Maria Chiara Tisi | ![]() |
![]() |
|||
384-P | INFECTIOUS AND THROMBOTIC COMPLICATIONS IN PERIPHERALLY INSERTED (PICCS) COMPARED TO SHORT TERM CENTRAL VENOUS CATHETERS IN ONCOHEMATOLOGIC PATIENTS: A REL GROUP (RETE EMATOLOGICA LOMBARDA) STUDY | Nicola Stefano Fracchiolla | ![]() |
![]() |
|||
385-P | USEFULNESS OF SERUM 1,3-B-D-GLUCAN FOR DIAGNOSIS OF INVASIVE FUNGAL DISEASE IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES: A RETROSPECTIVE ANALYSIS | Barbora Weinbergerova Fracchiolla | ![]() |
![]() |
|||
386-P | DIFFERENT ISOFORM LOCALIZATION GOVERNS SIGNALING QUALITY OF DECTIN-1 IN THE REGULATION OF ANTI-FUNGAL IMMUNITY | Ulf Schnetzke Fracchiolla | ![]() |
![]() |
|||
387-P | PRELIMINARY REPORT OF FUNGEMIA IN HEMATOLOGICAL MALIGNANCIES FROM SEIFEM-2015 SURVEY | Marianna Criscuolo Fracchiolla | ![]() |
![]() |
|||
388-P | PROGNOSTIC FACTORS IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES ADMITTED TO THE INTENSIVE CARE UNIT: EXPERIENCE WITH 335 PATIENTS FROM A SINGLE CENTER | Alfredo Rivas-Delgado Fracchiolla | ![]() |
![]() |
|||
389-P | SAFETY AND EFFICACY OF HUMAN T-LYMPHOTROPIC VIRUS 1 (HTLV-1) HYPERIMMUNE GLOBULIN AGAINST HTLV-1 INFECTION IN A HUMANIZED MOUSE MODEL. | Takuo Mizukami Fracchiolla | ![]() |
![]() |
|||
391-P | AUDIT OF TRANSFUSION PRACTICES IN PATIENTS RECEIVING AUTOLOGOUS STEM CELL TRANSPLANTATION AT UNIVERSITY HOSPITALS BIRMINGHAM | Aine BURKE Fracchiolla | ![]() |
![]() |
|||
393-P | IMPACT OF PROTHROMBIN COMPLEX CONCENTRATE (PCC) USE ON TRANSFUSION REQUIREMENTS AND BLOOD LOSS IN CARDIAC SURGERY | Allison Mo Fracchiolla | ![]() |
![]() |
|||
394-P | COMBINED PLASMA EXCHANGE AND ERYTHROCYTAPHERESIS FOR TREATMENT OF MULTIORGAN FAILURE DUE TO SUSPECTED FAT EMBOLISM SYNDROME IN SICKLE CELL DISEASE | Daniele Avenoso Fracchiolla | ![]() |
![]() |
|||
396-P | EFFECTS OF IMPLEMENTATION OF A MASSIVE TRANSFUSION PROTOCOL IN A TERTIARY REFERRAL HOSPITAL | Ioannis Giannoutsos Fracchiolla | ![]() |
![]() |
|||
397-P | LOW PREVALENCE OF ALLOIMMUNIZATION AFTER RED BLOOD CELL TRANSFUSION IN 182 CHILDREN WITH SICKLE CELL DISEASE. | Slimane Allali Fracchiolla | ![]() |
![]() |
|||
402-P | NEW MUTATION C.-140C>G IN 5´UTR OF ANKRD26 GENE IN PATIENTS WITH MILD FORM OF INHERITED THROMBOCYTOPENIA ASSOCIATED WITH MALIGNANCIES. | Silvia FERRARI Fracchiolla | ![]() |
![]() |
|||
403-P | MYCHOFENOLATE MOFETILE FOR THE TREATMENT OF CHILDREN WITH IMMUNE THROMBOCYTOPENIA AND EVANS SYNDROME. A RESTROSPECTIVE STUDY OF THE ITALIAN ASSOCIATION OF PEDIATRIC HEAMATOLOGY/ONCOLOGY GROUP | Maurizio Miano Fracchiolla | ![]() |
![]() |
|||
406-P | THE IMMUNOMODULATORY EFFECTS OF RETINIC ACID IN ADULT PATIENTS WITH IMMUNE THROMBOCYTOPENIA | Qi Feng | ![]() |
![]() |
|||
407-P | STUDIES ON PLATELET FUNCTION IN A GROUP OF CLL AND MCL PATIENTS TREATED WITH IBRUTINIB - PRELIMINARY RESULTS | Darek Jawniak Vaccari | ![]() |
![]() |
|||
408-P | CLINICAL CHARACTERISTICS AND TREATMENT PATTERN OF NEWLY DIAGNOSED PRIMARY IMMUNE THROMBOCYTOPENIA CASES IN THE UNITED KINGDOM IMMUNE THROMBOCYTOPENIA (ADULT) REGISTRY | Indraraj Umesh Doobaree | ![]() |
![]() |
|||
409-P | EFFICACY AND SAFETY OF RIVAROXABAN FOR NON-VALVULAR ATRIAL FIBRILLATION IN PATIENTS WITH SEVERE RENAL IMPAIRMENT | Sara Ali Doobaree | ![]() |
![]() |
|||
410-P | ORAL DIRECT ANTICOAGULANTS IN THE TREATMENT OF NONVALVULAR ATRIAL FIBRILLATION. RESULTS OF THE DAILY CLINICAL PRACTICE | Beatriz Perez Villardon | ![]() |
![]() |
|||
411-P | SWITCH FROM VKA, LMWH OR FONDAPARINUX TO DOACS IN THE CLINICAL PRACTICE. | Francesco cortiula Villardon | ![]() |
![]() |
|||
412-P | HIGH HEMOGLOBIN CONCENTRATIONS AND RISK OF THROMBOSIS: CAUSALITY OR CONFOUNDING? | Sæmundur Rögnvaldsson Villardon | ![]() |
![]() |
|||
414-P | ANNEXIN A5 M2 HAPLOTYPE: TO BE OR NOT TO BE, THAT´S THE QUESTION! | Rita Tenreiro Villardon | ![]() |
![]() |
|||
415-P | IRON METABOLISM IN PATIENTS WITH PORTAL THROMBOSES | Elena Lukina Villardon | ![]() |
![]() |
|||
416-P | PERIPHERALLY INSERTED CENTRAL VENOUS CATHETER-RELATED VENOUS THROMBOSIS IN PATIENTS WITH HEMATOLOGICAL DISEASES | Ana BOBAN Villardon | ![]() |
![]() |
|||
417-P | EQUATIONS FOR ESTIMATING GFR: COMPARING RENAL FUNCTION CATEGORISATION IN THE CATCH STUDY | Mette Stagaard Janas | ![]() |
![]() |
|||
418-P | A PROSPECTIVE EVALUATION OF THE IMPACT OF TRANSFUSION DEPENDENCY ON QUALITY OF LIFE AND SYMPTOM BURDEN IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES | Francesco Sparano Janas | ![]() |
![]() |
|||
422-P | PATIENT PREFERENCES, SURVEY OF HODGKIN LYMPHOMA SURVIVORS ON TREATMENT, ASSOCIATED BURDEN AND SIDE EFFECTS | Carolin Buerkle | ![]() |
![]() |
|||
423-P | UNDERESTIMATED IMPACT OF MILD COGNITIVE IMPAIRMENT IN "CLINICALLY FIT" OLDER PATIENTS WITH MALIGNANT HEMOPATHIES ADMITTED TO RECEIVE CHEMOTHERAPY | Dominique Bron Janas | ![]() |
![]() |
|||
424-P | WHAT DO PATIENT EXPERIENCE DATA REVEAL ABOUT THE DIAGNOSTIC JOURNEY FOR MYELOMA PATIENTS? FINDINGS FROM SECONDARY ANALYSIS OF NATIONAL CANCER PATIENT SURVEY DATA | Sarah Richard Janas | ![]() |
![]() |
|||
425-P | STREAMLINING OF THE CHEMOTHERAPY SERVICE WITH FOCUS ON DRUG SUPPLY AND PATIENT SAFETY | Heike Reinhardt Janas | ![]() |
![]() |
|||
426-P | INTERIM QUALITY OF LIFE RESULTS WITH VENETOCLAX (ABT-199/GDC-0199) MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY DEL(17P) CHRONIC LYMPHOCYTIC LEUKEMIA | Ling-I HSU Janas | ![]() |
![]() |
|||
526-P | IN VIVO ROLE OF ACTIVATION INDUCED CYTIDINE DEAMINASE (AID) EXPRESSION IN THE DEVELOPMENT OF PRECURSOR B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | Franziska Auer | ![]() |
![]() |
|||
528-P | THE HISTONE DEACETYLASE INHIBITOR GIVINOSTAT (ITF2357) HAS A POTENT ANTI-TUMOR ACTIVITY AGAINST CRLF2 REARRANGED LEUKEMIA | Giovanni Cazzaniga Janas | ![]() |
![]() |
|||
529-P | INSIGHTS INTO THE MOLECULAR EVOLUTION OF BCR-ABLP190 MEDIATED PRECURSOR B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | Franziska Auer Vaccari | ![]() |
![]() |
|||
530-P | THE ROLE OF CNOT3 AND THE ENTIRE CCR4-NOT COMPLEX IN TUMOR DEVELOPMENT | Carmen VICENTE | ![]() |
![]() |
|||
531-P | CAPTURE-BASED NEXT GENERATION SEQUENCING (NGS) IDENTIFIES ALSO RARE IG/TCR REARRANGEMENTS IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS | Marie Lorena | ![]() |
![]() |
|||
532-P | MIR-126 DRIVEN LEUKEMIA: A MURINE MODEL TO UNDERSTAND HUMAN B-ALL PATHOGENESIS | Matteo Maria | ![]() |
![]() |
|||
533-P | MUTATIONS IN TP53 AND JAK2 GENES ARE ASSOCIATED WITH POOR PROGNOSIS IN PEDIATRIC AND ADULT PATIENTS WITH B-CELL PRECURSOR ALL | Cristina Robledo | ![]() |
![]() |
|||
536-P | TARGETING BET FAMILY PROTEINS IMPROVES THE THERAPEUTIC EFFICACY OF BCL-2 INHIBITION IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | Sofie PEIRS NALDINI | ![]() |
![]() |
|||
538-P | DELETIONS OF IKZF1 GENE, BUT NOT GENETIC RISK GROUPS, DEFINED BY COPY-NUMBER ALTERATIONS, ARE PROGNOSTICALLY SIGNIFICANT FOR PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA ON ALL-MB 2008 PROTOCOL | Grigory TSAUR NALDINI | ![]() |
![]() |
|||
539-P | LACK OF PROGNOSTIC SIGNIFICANCE OF CD20 EXPRESSION IN ADULTS WITH PHILADELPHIA CHROMOSOME-NEGATIVE, B-CELL PRECURSOR ALL TREATED ACCORDING TO MRD-ORIENTED PROTOCOLS | Josep Maria | ![]() |
![]() |
|||
541-P | PRELEUKEMIC CLONES IN NPM1-MUTATED AML MAY BE ASSOCIATED WITH EVOLUTION TO MYELODYSPLASTIC SYNDROME (MDS) OR MYELOPROLIFERATIVE NEOPLASM (MPN) | Sarah morin | ![]() |
![]() |
|||
542-P | CLINICAL, HEMATOLOGICAL, BIOLOGIC AND MOLECULAR CHARACTERISTICS IN PATIENTS WHO DEVELOP ACUTE MYELOID LEUKEMIA FROM CHRONIC MYELOMONOCYTIC LEUKEMIA | Temeida Alendar Ribera | ![]() |
![]() |
|||
544-P | SOMATIC DDX41 P.R525H MUTATION CAUSES GROWTH DEFECT IN HEMATOPOIETIC CELLS | Hirotaka Matsui | ![]() |
![]() |
|||
545-P | WHOLE EXOME SEQUENCING REVEALS NOVEL CANDIDATE GENES IN FAMILIAL MDS/AML | Ana Rio-Machin Ribera | ![]() |
![]() |
|||
547-P | POOR PROGNOSIS MONOSOMIC AND TRISOMIC ACUTE MYELOID LEUKEMIA ASSOCIATES WITH CHECKPOINTS AND CDC20 DEREGULATION: A NOVEL LEUKEMOGENIC MECHANISM AND THERAPEUTIC TARGETS | Giorgia Simonetti Ribera | ![]() |
![]() |
|||
549-P | PHYSIOPATHOLOGICAL MECHANISM OF LEUKEMIC PREDISPOSITION IN ANKRD26-RD PATIENTS | Alessandro Donada | ![]() |
![]() |
|||
550-P | NOTCH SIGNALLING INHIBITION AS A MULTI-TARGET THERAPY TO OVERCOME BONE MARROW MICROENVIRONMENT-MEDIATED DRUG RESISTANCE IN AML | Paul Takam Kamga | ![]() |
![]() |
|||
552-P | ENANTIOMER-SPECIFIC AND PARACRINE LEUKEMOGENICITY OF MUTANT IDH METABOLITE 2-HYDROXYGLUTARATE | Anuhar Chaturvedi | ![]() |
![]() |
|||
553-P | INVOLVEMENT OF THE TRANSCRIPTION FACTOR ASCL2 IN NORMAL AND LEUKEMIC HEMATOPOIESIS | Mallorie Dépond Kamga | ![]() |
![]() |
|||
555-P | IN VIVO SHRNA SCREEN IDENTIFIES SPLICING FACTOR RBM25 AS A TUMOR SUPPRESSOR IN ACUTE MYELOID LEUKEMIA | Ying Ge | ![]() |
![]() |
|||
556-P | HIGH MTORC1 ACTIVITY DRIVES GLUCOSE METABOLISM ADDICTION AND SENSITIVITY TO G6PD INHIBITION IN ACUTE MYELOID LEUKEMIA CELLS | Laury Poulain | ![]() |
![]() |
|||
559-P | IDENTIFICATION OF A NOVEL STAT5 INHIBITOR TO INTERFERE WITH THE ONCOGENIC ACTIVITIES OF STAT5 IN AML | Bettina Wingelhofer | ![]() |
![]() |
|||
561-P | DOUBLE INACTIVATION OF TET2 AND TET3 INDUCES HYPOMETHYLATING AGENT-SENSITIVE ACUTE MYELOID LEUKEMIA | Koichiro Maie Kamga | ![]() |
![]() |
|||
562-P | NGS IDENTIFIES MUTATIONS PROGNOSTIC OF RELAPSE AFTER ALLO-SCT AND NOVEL CLONE EMERGENCE AT DISEASE RECURRENCE: IMPLICATIONS FOR STRATEGIES TO PREVENT POST ALLO-SCT RELAPSE. | Lynn Quek Kamga | ![]() |
![]() |
|||
563-P | HIGH PREDICTIVE VALUE OF COMBINED WT1 AND FLOW CYTOMETRY-BASED PRE TRANSPLANT MINIMAL RESIDUAL DISEASE ASSESSMENT IN ACUTE MYELOID LEUKEMIA | Fabio Guolo | ![]() |
![]() |
|||
565-P | DNMT3A AND IDH1 MUTATIONS WORSEN THE PROGNOSIS OF ELN GOOD RISK (CEBPA OR NPM1 MUTATED/FLT3 UNMUTATED) AML PATIENTS | Jana Marková Ribera | ![]() |
![]() |
|||
567-P | NANOG EXPRESSION AS A RESPONSIVE BIOMARKER DURING TREATMENT WITH HEDGEHOG SIGNAL INHIBITOR IN ACUTE MYELOID LEUKEMIA | Seiji Kakiuchi | ![]() |
![]() |
|||
569-P | AN EX VIVO NATIVE ENVIRONMENT PRECISION MEDICINE TEST SHOWS HIGH CLINICAL CORRELATION WITH RESPONSES TO FIRST LINE ACUTE MYELOID LEUKEMIA TREATMENT | Ana Espinosa | ![]() |
![]() |
|||
570-P | RECURSIVE PARTITIONING ANALYSIS FOR GENETIC STRATIFICATION AND PROGNOSTICATION OF ACUTE MYELOID LEUKAEMIA | Shaun Fleming Kamga | ![]() |
![]() |
|||
571-P | CD7 AND CD34 CO-EXPRESSION IDENTIFY A SUBPOPULATION OF NUCLEOPHOSMIN 1-MUTATED ACUTE MYELOID LEUKEMIA (NPM1+ AML) PATIENTS WITH INCREASED RISK OF RELAPSE. | Anna Porwit | ![]() |
![]() |
|||
575-P | THE ADDITION OF GEMTUZUMAB OZAGAMICIN (GO) TO INTENSIVE CHEMOTHERAPY SIGNIFICANTLY IMPROVES COMPLETE RESPONSES CR RATES AND OVERALL SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA | Giovanni Martinelli | ![]() |
![]() |
|||
577-P | PHARMACEUTICAL TARGETING OF PYRUVATE DEHYDROGENASE KINASES IN T(8;21) ACUTE MYELOID LEUKEMIA | Hüsün Kizilkaya Kamga | ![]() |
![]() |
|||
578-P | HOPX IS A HEMATOPOIETIC STEM CELL MARKER AND ITS HIGH EXPRESSION PREDICTS CHEMORESISTANCE IN DE NOVO ACUTE MYELOID LEUKEMIA PATIENTS | Chien-Chin Lin | ![]() |
![]() |
|||
580-P | LONGITUDINAL EVALUATION OF T-CELLS IN CLINICAL MONOCLONAL B-CELL LYMPHOCYTOSIS (MBL) | Sameer A. Parikh | ![]() |
![]() |
|||
580-LB | Mohamed Sorror | ![]() |
|
![]() |
|||
581-P | COPY NUMBER ANALYSIS OF THE BIRC3 GENE BY DROPLET DIGITAL PCR IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS WITH 11Q DELETION | Sara Raponi | ![]() |
![]() |
|||
586-P | IMPROVING THE DIFFERENTIAL DIAGNOSIS OF CD5+ B-LYMPHOPROLIFERATIVE DISORDERS | Andy Rawstron Parikh | ![]() |
![]() |
|||
587-P | REFINED KARYOTYPE-BASED PROGNOSTIC STRATIFICATION OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH A VERY LOW RISK GENETIC PROFILE | Ilaria Del Giudice | ![]() |
![]() |
|||
588-P | PRO-APOPTOTIC EFFECTS OF PRIMA-1MET CORRELATE WITH NOXA GENE INDUCTION IN CHRONIC LYMPHOCYTIC LEUKEMIA CELLS | Zuzana Jaskova Giudice | ![]() |
![]() |
|||
589-P | PILOT STUDY TO ASSESS REAGENT AND INSTRUMENT QUALITY FOR REPRODUCIBLE DIAGNOSIS OF CHRONIC LYMPHOCYTIC LEUKEMIA: AN ESCCA AND ERIC HARMONISATION PROJECT | Andy Rawstron | ![]() |
![]() |
|||
590-P | THE SYK\JAK INHIBITOR CERDULATINIB SHOWS PROMISING IN VITRO ACTIVITY IN CHRONIC LYMPHOCYTIC LEUKEMIA | Andrew STEELE | ![]() |
![]() |
|||
592-P | IBRUTINIB FOR RELAPSED CLL PATIENTS OLDER THAN 75 YEARS: PROVEN EFFICACY, TOXICITIES TO KNOW | Anne-Sophie MICHALLET Giudice | ![]() |
![]() |
|||
595-P | CHROMOSOME 8 ABNORMALITIES ARE ASSOCIATED WITH AN EVEN WORSE OUTCOME AND KARYOTYPE COMPLEXITY IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA AND TP53 ABERRATIONS | Gonzalo Blanco | ![]() |
![]() |
|||
598-P | NO IMPROVEMENT IN LONG-TERM OVERALL SURVIVAL AFTER THE INTRODUCTION OF CHEMO(IMMUNO)THERAPY FOR CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS BELONGING TO STEREOTYPED SUBSET #2 | Panagiotis Baliakas Giudice | ![]() |
![]() |
|||
601-P | ROCK AS THERAPEUTICAL TARGET FOR MORGANA LOW CML | Stefania Rocca | ![]() |
![]() |
|||
602-P | A NOVEL C-TERMINAL HSP90 INHIBITOR WITH THERAPEUTIC EFFECT IN IMATINIB RESISTANT CML. | Sanil Bhatia Ribera | ![]() |
![]() |
|||
604-P | MITOCHONDRIAL DNA MUTATIONS IDENTIFY CLONAL HETEROGENEITY IN CHRONIC MYELOID LEUKAEMIA | Ilaria Stefania Pagani | ![]() |
![]() |
|||
605-P | CLONAL STRUCTURES OF LEUKAEMIA STEM CELL POPULATIONS IN MYELOID BLAST PHASE CHRONIC MYELOID LEUKAEMIA | Dimitrios Karamitros Pagani | ![]() |
![]() |
|||
606-P | ROLE OF THE AURORA KINASE A AXIS IN IMATINIB RESISTANCE OF CHRONIC MYELOID LEUKEMIA CD34+ PROGENITORS | Manuela Mancini Pagani | ![]() |
![]() |
|||
610-P | THE INCIDENCE AND NATURAL HISTORY OF DASATINIB COMPLICATIONS IN THE TREATMENT OF CHRONIC MYELOID LEUKAEMIA | Lucy Fox Pagani | ![]() |
![]() |
|||
611-P | THE HOCT1/ABCB1 DIPLOTYPE IS ASSOCIATED WITH COMPLETE CYTOGENETIC RESPONSE AND TOLERABILITY TO IMATINIB IN PATIENTS AFFECTED BY CHRONIC MYELOID LEUKEMIA | Sara Galimberti Pagani | ![]() |
![]() |
|||
612-P | REAL-LIFE COMPARISON OF DASATINIB AND NILOTINIB AS SECOND-LINE THERAPY AFTER IMATINIB FAILURE FOR CHRONIC PHASE CML | Mario Tiribelli Pagani | ![]() |
![]() |
|||
613-P | FACTORS THAT INFLUENCE PATIENT WILLINGNESS TO ATTEMPT TREATMENT-FREE REMISSION IN CHRONIC MYELOID LEUKAEMIA | David Ross Pagani | ![]() |
![]() |
|||
614-P | GENETIC VARIABILITY OF OXIDATIVE STRESS AND DNA REPAIR GENES – POTENTIAL PROGNOSTIC AND THERAPEUTIC BIOMARKERS IN CHRONIC MYELOID LEUKEMIA | Ana Cristina Gonçalves | ![]() |
![]() |
|||
616-P | BCR-ABL1 TRANSCRIPT LEVEL ON DAY+28 CAN PREDICT EARLY MOLECULAR RESPONSE AT 3 MONTHS AND MAJOR MOLECULAR RESPONSE AT 12 MONTHS IN CHRONIC MYELOID LEUKEMIA PATIENTS WHO TREATED WITH FRONTLINE DASATINIB | Won Sik LEE | ![]() |
![]() |
|||
619-P | IMPACT OF BONE MARROW FIBROSIS IN RESPONSE TO AZACITIDINE IN 94 PATIENTS WITH MYELODISPLASTIC SYNDROMES (MDS), CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) AND ACUTE MYELOID LEUKEMIA | Alessandra Freyrie Gonçalves | ![]() |
![]() |
|||
620-P | AGE DISTRIBUTION OF PATIENTS WITH MYELODYSPLASTIC SYNDROME (MDS) IN GERMANY AND THEIR PROGNOSIS ACCORDING TO THE INTERNATIONAL PROGNOSTIC SCORING SYSTEM (IPSS): DATA FROM THE REGULAR CARE MDS REGISTRY | H Tilman Steinmetz | ![]() |
![]() |
|||
621-P | VALIDATION OF PROGNOSTIC SCORING SYSTEMS FOR MYELODYSPLASTIC SYNDROMES IN THE SWEDISH MDS-REGISTER | Daniel Moreno Berggren | ![]() |
![]() |
|||
622-P | EXPRESSION OF TUBB GENE IN MYELODYSPLASTIC SYNDROME WITH OR WITHOUT EVOLUTION TO LEUKEMIA | Yan MA Berggren | ![]() |
![]() |
|||
623-P | HIDDEN MDS: A PROSPECTIVE STUDY TO CONFIRM OR EXCLUDE MDS IN PATIENTS WITH ANEMIA OF UNCERTAIN ETIOLOGY. | Bastida Jose Maria | ![]() |
![]() |
|||
625-P | CLASSIFICATION OF MYELODYSPLASTIC SYNDROMES (MDS) IN DAILY PRACTICE: A POPULATION-BASED STUDY AMONG 8912 PATIENTS DIAGNOSED IN THE NETHERLANDS FROM 2001 TO 2014 | Avinash Dinmohamed Maria | ![]() |
![]() |
|||
626-P | LEVELS OF TRANSFUSION BURDEN AND ASSOCIATED COSTS FOR PATIENTS WITH TRANSFUSION-DEPENDENT MYELODYSPLASTIC SYNDROMES | Amy DeZern Maria | ![]() |
![]() |
|||
627-P | THE INCORPORATION OF COMORBIDITIES IN THE PROGNOSTICATION OF PATIENTS WITH LOWER-RISK MDS. | Teresa Knight Asorey | ![]() |
![]() |
|||
628-P | STROMAL MICROENVIRONMENT COMPONENTS DAMAGE IN PATIENTS WITH GRAFT FAILURE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELLS TRANSPLANTATION | Nataliya PETINATI | ![]() |
![]() |
|||
629-P | SPONTANEOUS REMISSION IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA - RETURN TO HEALTH OR TRANSITION INTO MALIGNANCY? | Eva-Stina Kairemo Asorey | ![]() |
![]() |
|||
632-P | A PHASE 1 SINGLE-ASCENDING-DOSE CLINICAL STUDY OF RA101495, A SUBCUTANEOUSLY ADMINISTERED SYNTHETIC MACROCYCLIC PEPTIDE INHIBITOR OF COMPLEMENT C5 FOR TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA | Jeffrey Johnston Asorey | ![]() |
![]() |
|||
633-P | THE PRESENCE OF A PNH CLONE INFLUENCES THE KINETICS OF RESPONSE TO IMMUNOSUPPRESSIVE THERAPY (IST) IN APLASTIC ANEMIA (AA) PATIENTS. | Thomas Nevill Asorey | ![]() |
![]() |
|||
638-P | IKAROS PROTEIN EXPRESSION IN BONE MARROW B AND T CELLS RATHER THAN MYELOMA CELLS PREDICTS OUTCOME AFTER LENALIDOMIDE-DEXAMETHASONE THERAPY | Arnold Bolomsky Asorey | ![]() |
![]() |
|||
639-P | CXCL13 CHEMOKINE – A NOVEL TARGET IN MULTIPLE MYELOMA MICROENVIRONMENT | Katia BEIDER Asorey | ![]() |
![]() |
|||
640-P | MESENCHYMAL STEM CELLS (MSC) PROMOTES TUMOR MICROENVIRONMENT TRANSFORMATION DRIVING GRANULOCYTE-LIKE MYELOID DERIVED SUPPRESSOR CELLS (G-MDSC) ACTIVATION IN SMOLDERING AND MULTIPLE MYELOMA PATIENTS | Daniele Tibullo Asorey | ![]() |
![]() |
|||
641-P | TARGETING OF BMI-1 WITH PTC-209 AFFECTS MYELOMA CELL GROWTH & SURVIVAL AND IMPAIRS THE TUMOUR MICROENVIRONMENT | Arnold Bolomsky Asorey | ![]() |
![]() |
|||
642-P | LENALIDOMIDE MAINTENANCE COUNTERACTS PD-1 ELEVATION ON LYMPHOCYTES IN MYELOMA PATIENTS | Sophia Danhof Maria | ![]() |
![]() |
|||
643-P | CIRCULATING SERUM MIRNA PROFILE IN AL AMYLOIDOSIS | Fedor Kryukov | ![]() |
![]() |
|||
644-P | PRECLINICAL EVALUATION OF ABBV-838, A FIRST-IN-CLASS ANTI-CS1 ANTIBODY-DRUG CONJUGATE FOR THE TREATMENT OF MULTIPLE MYELOMA | Kurt Gish Asorey | ![]() |
![]() |
|||
648-P | PHASE 1B STUDY OF AN ALTERNATIVE LIQUID FORMULATION OF ACY-1215 (RICOLINOSTAT) IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED OR RELAPSED-AND-REFRACTORY MULTIPLE MYELOMA | Tyce Havens | ![]() |
![]() |
|||
650-P | OUTCOME OF MYELOMA PATIENTS WITH DELETION 17P – IMPACT OF BASELINE CHARACTERISTICS, TREATMENT AND ADDITIONAL CHROMOSOMAL CHANGES | Maximilian Merz | ![]() |
![]() |
|||
651-P | CIRCULATING TUMOR DNA IN MULTIPLE MYELOMA | Even Holth Rustad | ![]() |
![]() |
|||
654-P | PROSPECTIVE COMORBIDITY AND FUNCTIONAL GERIATRIC ASSESSMENT (CF-GA) IN MULTIPLE MYELOMA (MM) PATIENTS (PTS): RESULTS FROM A MULTICENTER GERMAN STUDY GROUP MM (DSMM) TRIAL | Sandra Dold Rustad | ![]() |
![]() |
|||
657-P | PROSPECTIVE EVALUATION OF GERIATRIC ASSESSMENT TOOLS IN REAL-WORLD, UNSELECTED, ELDERLY PATIENTS WITH SYMPTOMATIC MYELOMA | Efstathios Kastritis | ![]() |
![]() |
|||
665-P | PROGNOSTIC FACTORS IN PATIENTS WITH MULTIPLE MYELOMA AND STANDARD-RISK CYTOGENETICS | Moritz Binder | ![]() |
![]() |
|||
666-P | CLINICAL CHARACTERISTICS AND LONG-TERM OUTCOME ON IMATINIB IN PATIENTS WITH MYELOID/LYMPHOID NEOPLASMS AND ASSOCIATED PDGFRB FUSION GENES IN CHRONIC OR BLAST PHASE | Georgia METZGEROTH Rustad | ![]() |
![]() |
|||
667-P | THROMBOTIC RISK IN IDIOPATHIC ERYTHROCYTOSIS IS LOWER THAN IN POLYCYTHEMIA VERA BUT HIGHER THAN IN GENERAL POPULATION. | Maria Luigia Randi | ![]() |
![]() |
|||
669-P | COMPARISON OF GENOMIC DNA-BASED VS. MESSENGER RNA-BASED KIT D816V MUTATION ANALYSIS REVEALS LARGE DIFFERENCES BETWEEN BLOOD AND BONE MARROW IN SYSTEMIC MASTOCYTOSIS | Thomas Kristensen Randi | ![]() |
![]() |
|||
670-P | 3167 NEWLY DIAGNOSED MPN PATIENTS, A REPORT FROM THE SWEDISH MPN REGISTRY | Björn Andreasson Randi | ![]() |
![]() |
|||
671-P | PREDICTIVE ROLE OF CIRCULATING LEUCOCYTE-PLATELET AGGREGATES FOR THROMBOEMBOLIC COMPLICATIONS IN PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS: A PROSPECTIVE STUDY | Dijana Šefer | ![]() |
![]() |
|||
672-P | PREDICTORS FOR RESPONSE TO RUXOLITINIB IN REAL-LIFE: AN OBSERVATIONAL INDEPENDENT STUDY ON 266 PATIENTS WITH MYELOFIBROSIS | Nicola Polverelli | ![]() |
![]() |
|||
676-P | PROGNOSTIC IMPACT OF INTEGRATED GENOMIC PROFILING IN ADULT T-CELL LEUKEMIA/LYMPHOMA | Keisuke Kataoka | ![]() |
![]() |
|||
677-P | HNRNP K: A NOVEL ONCOGENE THAT DRIVES C-MYC-DEPENDENT LYMPHOMAS AS A POTENTIAL THERAPY TARGET | Miguel Gallardo Randi | ![]() |
![]() |
|||
678-P | GENOMIC PROFILING REVEALS SPATIAL HETEROGENEITY IN FOLLICULAR LYMPHOMA: IMPLICATIONS FOR PRECISION MEDICINE. | Shamzah Araf Randi | ![]() |
![]() |
|||
679-P | SOMATIC MUTATION PROFILING FOR PROGNOSIS AND TREATMENT STRATIFICATION OF DIFFUSE LARGE B-CELL LYMPHOMA IN THE REMODL-B TRIAL | Ming Qing Du | ![]() |
![]() |
|||
680-P | ADHESION MOLECULE JAM-C: A POTENTIAL TARGET FOR MANTLE CELL LYMPHOMA THERAPEUTICS | Thomas Matthes Randi | ![]() |
![]() |
|||
681-P | ATM GENE MUTATIONS REPRESENT A HALLMARK OF MANTLE CELL LYMPHOMA BUT DO NOT IMPACT PATIENTS´ SURVIVAL | Andrea MARECKOVÁ Randi | ![]() |
![]() |
|||
683-P | TP53 AND KMT2D MUTATIONS PREDICT PFS IN MCL PATIENTS TREATED WITH HIGH-DOSE THERAPY AND AUTOLOGOUS TRANSPLANTATION: RESULTS FROM THE MCL0208 PHASE III TRIAL FROM FONDAZIONE ITALIANA LINFOMI (FIL) | Simone Ferrero | ![]() |
![]() |
|||
684-P | DECIPHERING THE IMPACT OF IDELALISIB ON FOLLICULAR LYMPHOMA AND ITS IMMUNE MICROENVIRONMENT | Patricia Pérez-Galán Randi | ![]() |
![]() |
|||
685-P | MIR-34A PREVENTS LUNG INJURY IN BLEOMYCIN INDUCED PULMONARY FIBROSIS | Raanan Bulvik Du | ![]() |
![]() |
|||
686-P | INTERIM ANALYSIS OF POST MARKETING SURVEILLANCE OF YTTRIUM-90 IBRITUMOMAB TIUXETAN IN JAPANESE PATIENTS WITH RELAPSED OR REFRACTORY INDOLENT B-CELL NON-HODGKIN LYMPHOMA OR MANTLE CELL LYMPHOMA | Rumiko Kanzaki Randi | ![]() |
![]() |
|||
687-P | PATIENTS WITH FOLLICULAR LYMPHOMA (FL) SHOWING A DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) COMPONENT HAVE AN INTERMEDIATE OUTCOME BETWEEN FL AND DLBCL | Laura Magnano Randi | ![]() |
![]() |
|||
688-P | DISTINCT INCREASING TREND AND BIRTH-COHORT EFFECT OF FOLLICULAR LYMPHOMA INCIDENCE IN TAIWAN: EPIDEMIOLOGICAL ANALYSES AND IMPLICATIONS | Shang-Ju Wu | ![]() |
![]() |
|||
689-P | LONG-TERM OUTCOMES OF 131I-RITUXIMAB RADIOIMMUNOTHERAPY IN FOLLICULAR NON-HODGKIN LYMPHOMA: TEN YEAR UPDATE ON TOXICITY, TIME-TO-NEXT-TREATMENT AND SURVIVIAL OF THE PHASE II INITIAL STUDY | Murali Kesavan | ![]() |
![]() |
|||
690-P | LONG TERM OUTCOMES IN PRIMARY OCULAR ADNEXAL MUCOSA-ASSOCIATED LYMPHOID TISSUE LYMPHOMAS (POAML): A LARGE SINGLE INSTITUTE COHORT STUDY. | Amrita Desai | ![]() |
![]() |
|||
691-P | EARLY TRANSFORMATION IN LOW-GRADE LYMPHOMAS AND ITS ADVERSE PROGNOSTIC SIGNIFICANCE ON SURVIVAL | Luis Miguel Juárez | ![]() |
![]() |
|||
692-P | OFATUMOMAB FOR THE TREATMENT OF EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA OF THE MUCOSA-ASSOCIATED LYMPHOID TISSUE (MALT LYMPHOMA): THE O-MA1 STUDY | Barbara Kiesewetter | ![]() |
![]() |
|||
694-P | FINAL RESULTS OF IHC ANALYSIS AND PROGNOSTIC FACTORS IN POST TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS AFTER SOLID ORGAN TRANSPLANTATION | Manali Kamdar Juárez | ![]() |
![]() |
|||
695-P | IMPROVED OUTCOMES WITH HIGH DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANSPLANT IN PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA WITH PRESERVATION OF COGNITIVE FUNCTION | Shireen Kassam Juárez | ![]() |
![]() |
|||
697-P | NONPEGHYLATED LIPOSOMAL DOXORUBICIN AS A COMPONENT OF R-CHOP IS EFFECTIVE AND SAFE IN THE TREATMENT OF A CARDIAC HIGH-RISK AND ELDERLY LYMPHOMA PATIENTS | Luigi Rigacci Juárez | ![]() |
![]() |
|||
698-P | METHYLATION OF CELL-FREE CIRCULATING DNA IN PLASMA PREDICTS POOR OUTCOME IN DIFFUSE LARGE B-CELL LYMPHOMA | Lasse Sommer | ![]() |
![]() |
|||
701-P | DIFFUSE LARGE B-CELL LYMPHOMA IN THE RITUXIMAB ERA: REAL LIFE ANALYSIS OF PATIENTS WITH REFRACTORY DISEASE OR RELAPSE | Bente Arboe Kristensen | ![]() |
![]() |
|||
702-P | CENTRAL NERVOUS SYSTEM INTERNATIONAL PROGNOSTIC INDEX IN DIFFUSE LARGE B-CELL LYMPHOMA | Naoto Tomita Kristensen | ![]() |
![]() |
|||
704-P | DETECTION OF BONE MARROW INVOLVEMENT OF DLBCL - COMPARISON OF PET-CT AND BONE MARROW BIOPSY | Yuki Nakajima | ![]() |
![]() |
|||
707-P | A NOVEL QUANTITATIVE PCR APPROACH TARGETING INSERTION/DELETION POLYMORPHISMS (INDEL-PCR) FOR CHIMERISM QUANTIFICATION: FINALLY HIGH SENSITIVITY AND QUANTIFICATION CAPACITY TOGETHER | Almudena Navarro-Bailón Kristensen | ![]() |
![]() |
|||
708-P | A NEW APPROACH OF DUAL-SCT WITH UNMANIPULATED HAPLO-IDENTICAL GRAFT AND UNRELATED CORD BLOOD IN PATIENTS WITH HEMATOLOGICAL DISORDERS | Depei Wu Kristensen | ![]() |
![]() |
|||
709-P | RECIPIENT CCR5 GENETIC VARIATION PREDICTS TRANSPLANT OUTCOMES AFTER HLA-MATCHED UNRELATED DONOR BONE MARROW TRANSPLANTATION. | Tomohiro Horio Kristensen | ![]() |
![]() |
|||
710-P | PRESUMABLY FALSE POSITIVE MINIMAL RESIDUAL DISEASE (MRD) QPCR RESULTS AFTER ALLOGENEIC SCT UNCOVERED BY NEXT GENERATION SEQUENCING (NGS) | Michaela Kotrová Kristensen | ![]() |
![]() |
|||
711-P | PRE-EMPTIVE THERAPY WITH IFN-?-2B FOR ACUTE LEUKEMIA PATIENTS WITH HIGH RISK OF RELAPSING TENDENCY POST ALLO-HSCT | Depei Wu Kristensen | ![]() |
![]() |
|||
712-P | A STUDY OF RHTPO IN COMBINATION WITH CHEMOTHERAPY AND G-CSF FOR PERIPHERAL BLOOD PROGENITOR CELL MOBILIZATION IN PATIENTS WITH RELAPSED NON-HODGKIN LYMPHOMA | Haitao Bai Kristensen | ![]() |
![]() |
|||
713-P | A POLYCLONAL POPULATION OF PIGA MUTANT CD52 AND GPI-ANCHOR NEGATIVE T-CELLS CAN GIVE EARLY IMMUNE PROTECTION AFTER ALEMTUZUMAB-BASED T-CELL DEPLETED ALLOGENEIC STEM CELL TRANSPLANTATION | Inge JEDEMA Kristensen | ![]() |
![]() |
|||
714-P | WHICH CONDITIONING REGIMEN IS MORE EFFECTIVE FOR HIGH-RISK PATIENTS WITH AML/MDS : COMPARING LOW-DOSE DECITABINE COMBINED WITH MODIFIED BUCY WITH MODIFIED BUCY FOLLOWED BY ALLO-HSCT | Depei Wu Kristensen | ![]() |
![]() |
|||
715-P | ELEVATED EXPRESSION OF TIM-3 ON CD8 T CELLS CORRELATES WITH CYTOMEGALOVIRUS REACTIVATION AFTER ALLOGENIC STEM CELL TRANSPLANTATION | Depei Wu Kristensen | ![]() |
![]() |
|||
716-P | INTERFERON-GAMMA GENE POLYMORPHISM ASSOCIATE WITH MORTALITY AND GRAFT-VERSUS-HOST DISEASE SEVERITY IN HLA-MATCHED SIBLING BONE MARROW TRANSPLANTATION | Maria Virginia | ![]() |
![]() |
|||
718-P | BASELINE LABORATORY VARIABLES SERVE AS POTENT PREDICTORS OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION RELATED MORTALITY | Roni SHOUVAL | ![]() |
![]() |
|||
720-P | COMPARING TIME-DEPENDENT PREDICTIVE PERFORMANCE OF ALLOGENEIC HSCT RISK SCORING SYSTEMS | Joshua Fein Palau | ![]() |
![]() |
|||
721-P | PROPHYLACTIC DLI VS NO DLI FOR REFRACTORY ACUTE LEUKEMIA UNDERGOING ALLO-HSCT WITH SEQUENTIAL INTENSIFIED CONDITIONING | Qifa Liu Palau | ![]() |
![]() |
|||
722-P | THE PRE-TRANSPLANT BIOMARKER RISK INDEX BASED ON SERUM FERRITIN, ALBUMIN AND CRP CAN PREDICT OUTCOMES INDEPENDENTLY OF THE HCT-CI AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION | Tatsuya Suwabe Palau | ![]() |
![]() |
|||
723-P | HAPLOIDENTICAL TRANSPLANTATION FOR PEDIATRIC PATIENTS WITH ACQUIRED SEVERE APLASTIC ANEMIA | Shuning Zuo Palau | ![]() |
![]() |
|||
725-P | MINIMAL RESIDUAL DISEASE AND GRAFT-VERSUS-HOST DISEASE GUIDED SEQUENTIAL CHEMOTHERAPY PLUS DONOR LYMPHOCYTE INFUSION COULD IMPROVE SURVIVAL OF PATIENTS WITH ACUTE LEUKEMIA WHO RELAPSED AFTER ALLO-HSCT | Chen Hua Yan | ![]() |
![]() |
|||
727-P | BIFURCATION INTO HEMATOPOIETIC STEM CELL TYPES IS DEPENDENT UPON THE DEVELOPMENTAL SIGNALING MOLECULES | Mihaela CRISAN Palau | ![]() |
![]() |
|||
728-P | LACK OF MIR-127 DOWN-REGULATION IN THE TRANSITION FROM HEMATOPOIETIC STEM CELLS TO MULTI-POTENT PROGENITORS LEADS TO PANCYTOPENIA AND DEFECTIVE SELF-RENEWAL | Francesca Ficara Palau | ![]() |
![]() |
|||
729-P | NAMPT-NAD+-SIRT2 PATHWAY-TRIGGERED DEACETYLATION OF LMO2 PROTEIN IS INDISPENSABLE IN THE EARLY HEMATOPOIESIS THROUGH COMPLETE TAL1 COMPLEX FORMATION | Tatsuya Morishima | ![]() |
![]() |
|||
731-P | EXPRESSION OF BCL2, BUT NOT STAT5 SIGNALING, RESCUES LYMPHOPOIESIS IN THE ABSENCE OF HHEX | Jacob T | ![]() |
![]() |
|||
732-P | ANAMORSIN IS ESSENTIAL FOR B-CELL TERMINAL DIFFERENTIATION | Yuri Hamanaka | ![]() |
![]() |
|||
733-P | DOWNREGULATION OF CD44 FUNCTIONALLY DEFINES HUMAN T-CELL COMMITMENT | Kirsten Canté-Barrett | ![]() |
![]() |
|||
734-P | KNOCKDOWN OF THE ADHESION G-PROTEIN COUPLED RECEPTOR 56 IMPAIRS HUMAN CORD BLOOD STEM AND PROGENITOR CELL FUNCTION | Lixiazi He Palau | ![]() |
![]() |
|||
735-P | DISSECTING THE ROLE OF THE MICROENVIRONMENT IN APLASTIC ANEMIA USING AN IN VIVO HAEMATOPOIETIC STEM CELL NICHE MODEL | Ilaria Marina Michelozzi | ![]() |
![]() |
|||
737-P | EFFICIENT GENOME EDITING OF MOUSE HEMATOPOIETIC CELLS USING CRISPR/CAS9 TECHNOLOGY | Evgenia Sarrou | ![]() |
![]() |
|||
738-P | COMPREHENSIVE PROTEOMIC ANALYSIS OF HUMAN ERYTHROPOIESIS | Emilie-Fleur GAUTIER | ![]() |
![]() |
|||
740-P | STAPHYLOCOCCUS AUREUS PROTEIN ISDH INHIBITS THE CD163 PATHWAY FOR HAPTOGLOBIN-FACILITATED HEMOGLOBIN SCAVENGING | Kirstine Lindhardt Madsen | ![]() |
![]() |
|||
742-P | AG-519 IS A POTENT ACTIVATOR OF MUTANT PYRUVATE KINASE ASSOCIATED WITH HEMOLYTIC ANEMIA | Charles Kung Madsen | ![]() |
![]() |
|||
743-P | REDPLEX: A TARGETED NEXT GENERATION SEQUENCING-BASED DIAGNOSIS FOR PATIENTS WITH HEREDITARY HEMOLYTIC ANEMIAS | Roberta Russo Madsen | ![]() |
![]() |
|||
745-P | ELEVATED PLASMA ASYMMETRIC DIMETHYLARGININE LEVELS IN CHILDREN WITH BETA-THALASSEMIA MAJOR MAY BE AN EARLY MARKER FOR ENDOTHELIAL DYSFUNCTION | Orhan GURSEL Madsen | ![]() |
![]() |
|||
747-P | PAROXYSMAL NOCTURNAL HEMOGLOBINURIA SCREENING PRACTICE FROM UK CENTRES: A REPORT FROM THE UK PNH NETWORK | Morag griffin Michelozzi | ![]() |
![]() |
|||
748-P | DIAGNOSTIC VALUES FOR IRON DEFICIENCY ANEMIA IN CHILDREN AND WOMEN USING SERUM HEPCIDIN AND ZINC PROTOPORPHYRIN (ZPP) | Giridhar Kanuri Madsen | ![]() |
![]() |
|||
749-P | UTILITY OF RED CELL INDICES TO DIAGNOSE IRON DEFICIENCY IN RURAL INDIAN CHILDREN | Swaratika majumdar Madsen | ![]() |
![]() |
|||
751-P | SEARCH AND YOU SHALL FIND – VARIANT HEMOCHROMATOSIS GENE MUTATIONS AS A CAUSE OF HYPERFERRITINEMIA IN BLOOD DONORS | Adam Høgsbro | ![]() |
![]() |
|||
752-P | A PHASE 1, SINGLE AND MULTIPLE ASCENDING DOSE STUDY OF SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF AG-519, AN ALLOSTERIC ACTIVATOR OF PYRUVATE KINASE-R IN HEALTHY SUBJECTS | Ann Barbier | ![]() |
![]() |
|||
753-P | ANALYSIS OF MOLECULAR MECHANISMS OF DOMINANT-INTERFERING FAS MUTATIONS | Daniel Schäfer Laursen | ![]() |
![]() |
|||
754-P | UNSMAKING PRIMARY IMMUNE DEFICIENCIES IN EARLY-ONSET EVANS SYNDROME USING IMMUNOPHENOTYPING AND NGS: TOWARDS A CLINICAL AND GENETIC CLASSIFICATION | Nathalie Aladjidi Laursen | ![]() |
![]() |
|||
755-P | MRI SKELETAL MANIFESTATIONS IN GAUCHER DISEASE: UTILITY OF SPANISH-MRI (S-MRI) SCORE AT DIAGNOSIS AND FOLLOW-UP | Marcio Andrade-Campos Laursen | ![]() |
![]() |
|||
756-P | SEVUPARIN DEMONSTRATES BINDING TO KEY ADHESION RECEPTORS INVOLVED IN PATHOGENESIS OF SICKLE CELL DISEASE | Maria Lindgren Laursen | ![]() |
![]() |
|||
757-P | GLUTATHIONE S TRANSFERASE GENE POLYMORPHISMS AND THE RISK OF CNS COMPLICATIONS OF SICKLE CELL DISEASE IN EGYPTIAN PATIENTS | Hend Ellithy Michelozzi | ![]() |
![]() |
|||
760-P | INCREASED LEVELS OF CIRCULATING IMMATURE GRANULOCYTES IN SEPSIS HAVE A SIGNIFICANT IMPACT ON SURVIVAL: RESULTS OF THE FRENCH MULTICENTRIC SEPTIFLUX 2 STUDY | Estelle GUERIN Laursen | ![]() |
![]() |
|||
761-P | USEFULNESS OF A THIRTY ONE-GENE PANEL BY NEXT-GENERATION SEQUENCING FOR THE MOLECULAR DIAGNOSTIC OF INHERITED BLEEDING COAGULATION DISORDERS | Jose Maria BASTIDA | ![]() |
![]() |
|||
762-P | APPLICATION OF A MOLECULAR DIAGNOSTIC ALGORITHM FOR HEMOPHILIA A AND B USING NEXT-GENERATION SEQUENCING OF THE WHOLE F8, F9 AND VWF GENES. | Bastida Jose | ![]() |
![]() |
|||
763-P | ASSAY DISCREPANCY IN MILD HAEMOPHILIA A PATIENTS WITH MUTATIONS IN FVIII A DOMAIN | Alenka Trampuš Bakija | ![]() |
![]() |
|||
764-P | ARTHROPATHY IN PATIENTS WITH MODERATE AND SEVERE VON WILLEBRAND DISEASE | Karin van Galen | ![]() |
![]() |
|||
765-P | A COMPREHENSIVE NEXT GENERATION SEQUENCING TEST FOR THE DIAGNOSIS OF INHERITED BLEEDING, THROMBOTIC AND PLATELET DISORDERS | Suthesh Sivapalaratnam Galen | ![]() |
![]() |
|||
766-P | THE ROLE OF CD72 IN THE REGULATION OF B CELL ACTIVATION THROUGH CD40 IN PRIMARY IMMUNE THROMBOCYTOPENIA | Mingen Lyu | ![]() |
![]() |
|||
768-P | QUALITATIVE AND QUANTITATIVE ANALYSIS OF INTRAHEPATIC BLOOD FLOW CHANGES IN PATIENTS WITH HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT) | Roland Schelker BASTIDA | ![]() |
![]() |
|||
771-P | RECOMBINANT THROMBOMODULIN AMELIORATES HEMATOLOGICAL MALIGNANCY-INDUCED DISSEMINATED INTRAVASCULAR COAGULATION MORE PROMPTLY THAN CONVENTIONAL THERAPY WITHOUT CAUSING SEVERE HEMORRHAGIC EVENTS | Naoki Kurita Galen | ![]() |
![]() |
|||
772-P | EXTRACELLULAR HISTONES ENHANCE FACTOR XA MEDIATED PROTHROMBIN ACTIVATION WITHOUT PHOSPHOLIPID REQUIREMENT | Yasmina Sahraoui Galen | ![]() |
![]() |
|||
773-P | PHORBOL 12-MYRISTATE-13-ACETATE INDUCES VON WILLEBRAND FACTOR PROPEPTIDE RELEASE FROM ENDOTHELIAL CELLS FROM 2 DISTINCT COMPARTMENTS | Ruben Bierings Galen | ![]() |
![]() |
|||
774-P | NEWLY DIAGNOSED PLASMA CELL DYSCRASIAS ARE ASSOCIATED WITH ENHANCED TF PATHWAY ACTIVATION, THROMBIN GENERATION AND INCREASED CONCENTRATION OF PROCOAGULANT MICROPARTICLES | Despoina Fotiou BASTIDA | ![]() |
![]() |
|||
775-P | ROLE OF ROTATIONAL THROMBELASTOMETRY (ROTEM®) IN RAPID ESTIMATION OF RIVAROXABAN DRUG LEVEL | Hun Chuah Galen | ![]() |
![]() |
|||
778-P | INCIDENCE OF PERIPHERAL CIRCULATING CELLS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PHENOTYPE A FIRST EPISODE OF CEREBRAL SINUS VEIN THROMBOSIS: RESULTS FROM A PROSPECTIVE MULTICENTER STUDY | Mariasanta Napolitano | ![]() |
![]() |
|||
779-P | REGULATION OF WEIBEL-PALADE BODY EXOCYTOSIS FROM ENDOTHELIAL CELLS BY SYNTAXIN-3 AND STXBP5 CONTAINING SNARE COMPLEXES. | Ruben Bierings | ![]() |
![]() |
|||
780-P | COMPARISON OF QUALITY OF LIFE BETWEEN LONG-TERM SURVIVORS OF INDOLENT AND AGGRESSIVE LYMPHOMA: RESULTS OF A SINGLE CENTER PROSPECTIVE COHORT STUDY | Seok Jin Kim | ![]() |
![]() |
|||
781-P | IMPACT OF IRON DEFICIENCY ON QUALITY OF LIFE AND WORK CAPACITY OF WOMEN | Lucilia Caramelo Kim | ![]() |
![]() |
|||
782-P | IRON DEFICIENCY: UNDERSTANDING PERCEPTIONS OF SUFFERERS AND THE GENERAL PUBLIC | Lucilia Caramelo Kim | ![]() |
![]() |
|||
784-P | THE RELATIVE BURDEN OF AL AMYLOIDOSIS ON HEALTH-RELATED QUALITY OF LIFE | Kristen L. McCausland | ![]() |
![]() |
|||
785-P | OUTCOME OF PATIENTS WITH RELAPSED/REFRACTORY LYMPHOMA IN A LARGE COHORT INSIDE A PHASE 1 CLINIC DEPARTMENT. | Jean-Marie Michot McCausland | ![]() |
![]() |
|||
787-P | HEALTH-RELATED QUALITY OF LIFE ASSESSMENT IN LONGITUDINAL STUDIES INCLUDING MULTIPLE MYELOMA PATIENTS: A CRITICAL REVIEW OF INTERPRETING CHANGES OF SCORES OBTAINED BY EORTC QLQ-C30 | Lene Kongsgaard Nielsen | ![]() |
![]() |
|||
2239-LB | Giovanni Cazzaniga | ![]() |
|
![]() |
|||
2242-LB | David Britton | ![]() |
|
![]() |
|||
2244-LB | Claudio Cerchione | ![]() |
|
![]() |
|||
2249-LB | Jeffrey Johnston | ![]() |
|
![]() |
|||
2251-LB | Rainer Hubmann | ![]() |
|
![]() |
|||
2253-LB | K. Byrgazov | ![]() |
|
![]() |
|||
2255-LB | Giovanni Caocci | ![]() |
|
![]() |
|||
2258-LB | Claudio Cerchione | ![]() |
|
![]() |
|||
2264-LB | Monika Klimkowska | ![]() |
|
![]() |
|||
2266-LB | Yohei Kanamori | ![]() |
|
![]() |
|||
2268-LB | S. Ekwattanakit | ![]() |
|
![]() |
June 9th - June 12th 2016 Copenhagen
![]() |
![]() |
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. ![]() To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress. ![]() |
![]() |
||
![]() |
|